전체 8345
-
- Town Hall Meeting on the Peer Review Initiative (NIH Only)
-
- - Dr. Jeremy Berg and Dr. Larry Tabak (2010/11/18)
- - Category : Town Hall (NIH Only)
- An update on the Peer Review Initiative presented by Dr. Jeremy Berg (NIGMS) and Dr. Larry Tabak (NIDCR), co-chairs of the Steering Committee Working Group (SC WG) on peer review.
See Enhancing Peer Review for more information.
Town Hall Meeting on the Peer Review Initiative (NIH Only)
-
- Addiction to an Aberrant Network: IRF4 in Multiple Myeloma
-
- - Shafer, Art.
National Institutes of Health (U.S.). Immunology Interest Group. (2010/11/18) - - Category : Immunology
- - Shafer, Art.
- Dr. Shaffer has a fundamental interest in the application of basic immunology to problems involving the dysregulation of the immune system, especially with regard to cancer. He developed his abiding interest in basic immunology as a graduate student at Johns Hopkins under the tutelage of then new faculty member Mark Schlissel, studying the targeting and timing of V(D)J recombination during early B cell development.
Continuing to pursue his interest in understanding the interplay of normal and pathological immune system development, Dr. Shaffer became a post-doctoral fellow in the laboratory of Dr. Louis Staudt in the National Cancer Institute in 1996. His first effort was to uncover the genes lying downstream of a transcriptional repressor, BCL6, which is not only essential for normal germinal B cell differentiation but is also a target of recurrent translocations in diffuse large B cell lymphoma, a malignancy of germinal center B cells. Employing the then-novel technology of gene expression microarrays developed in the Staudt lab, Dr. Shaffer found that BCL6 represses genes involved in B cell activation, inflammation, and terminal plasmacytic differentiation, thereby enforcing the germinal center B cell program. Dr. Shaffer made a fundamental insight into the pathogenesis of diffuse large B cell lymphoma by demonstrating that BCL-6 represses Blimp-1, an essential regulator of plasmacytic differentiation. Normally, BCL-6 is silenced during plasmacytic differentiation, but translocations in diffuse large B cell lymphoma prevent this. BCL-6 expression in these lymphomas blocks Blimp-1, thereby trapping the malignant B cells at an intermediate stage of differentiation, halfway between the germinal center B cell and the plasma cell. Such diffuse large B cell lymphomas, known as the activated B cell-like (ABC) subtype, have a plasmablastic phenotype, express AID highly, and accumulate a variety of other cooperating oncogenic mutations.
After this initial success in combining gene expression profiling and the study of B cell differentiation, Dr. Shaffer went on to elucidate the action of several additional critical B cell differentiation-related transcription factors. His work, along with the efforts of many excellent collaborators has shown that: - the critical plasma cell transcriptional repressor, Blimp-1, shuts down the B cell gene expression program and forms a negative feedback loop with BCL6 to lock cells into a terminally differentiated state. - the plasma cell transcriptional activator, XBP1, is a master regulator of the secretory system and, surprisingly, also increases cell size and protein translation, allowing for maximal antibody synthesis. - the transcription factor IRF4 coordinates B cell isotype switching and initiates plasma cell differentiation by inducing critical regulators of these processes, including AID and Blimp-1.
As a result of these experimental successes as a post-doc, Dr. Shaffer was appointed as a Staff Scientist in 2001, and has enjoyed connecting with the broader NIH immunology community through the Immunology Interest Group and the late, lamented B cell Workshop. He remains fundamentally convinced of the pre-eminence of the alphabetically superior lymphocyte.
In today？？？s lecture, Dr. Shaffer will illustrate how another genomic-scale technology, the Achilles？？？ heel RNA interference genetic screen, has revealed the pathological role of B cell-specific transcription factors in multiple myeloma, a malignancy of plasma cells. These observations exemplify a new notion in cancer biology, termed non-oncogene addiction.
For more information, visit
The Immunology Interest Group
Addiction to an Aberrant Network: IRF4 in Multiple Myeloma
-
- Knowing Your Boss
-
- - Jennifer Alfonso (2010/11/18)
- - Category : Work/Life Center
- NIH Work Life Seminar
Much of the focus of employees is how their boss manages them. Not enough thought and energy is given to how an employee manages their relationship with their supervisor or ？？？boss.？？？ ？？？Managing Up？？？ is defined by John Gobarro and John Kotter (Harvard Business Review) as ？？？a process of consciously working with your superior to obtain the best possible results for you, your boss and your company.？？？ This seminar is designed to introduce you to the important aspects of your relationship with your boss and how to maximize your ability to be effective.
For more information, visit
http://wlc.od.nih.gov
Knowing Your Boss
-
- Thrift Savings Plan Seminars
-
- - Paula Gradwell, Federal Retirement Thrift Investment Board (2010/11/18)
- - Category : Special
This is a two-part briefing. Part 1 covers the advantages of participating in the Thrift Savings Plan (TSP) and provides information on the TSP Investment Funds and Participant Statements. Part 2 provides information on the loan program, in-service withdrawals, post-service withdrawals, spouse？？？s rights, and death benefits.
Note: This presentation was current as of May 29, 2008.
Thrift Savings Plan Seminars
-
- Leading with Diversity and Inclusion (NIH Only)
-
- - Christopher J. Metzler, Ph.D, Georgetown University (2010/11/18)
- - Category : Diversity (NIH Only)
- The NIH Diversity Seminar Series focuses on enhancing diversity and promoting organizational effectiveness.
Speaker:
Christopher J. Metzler, Ph.D
Associate Dean of Human Resources and Diversity Studies at Georgetown University
Leading with Diversity and Inclusion (NIH Only)
-
- Staff Scientist Clinician Committee Town Hall Meeting (NIH Only)
-
- - Michael Difilippantonio and Dr. Joan Schwartz (2010/11/18)
- - Category : Town Hall (NIH Only)
- The purpose of this meeting is to introduce the Council of Representatives, discuss the successes of the past year and identify areas of concern, ratify the Constitution and By-Laws and hold a question-and-answer period with a panel of NIH representatives, including Dr. Joan P. Schwartz, Ph.D. (Assistant Director, Office of Intramural Research).
Staff Scientist Clinician Committee Town Hall Meeting (NIH Only)
-
- Initiatives to Promote Scientific Success in the NIH Intramural Program
-
- - Women Scientist Advisors Committee (WSA) and the Office of Research on Womens Health (ORWH) (2010/11/18)
- - Category : Conferences
- A forum to discuss the initiatives underway for promoting career success and work/life balance for all NIH employees.
After viewing the video cast, please click here to complete a short survey: http://www.surveymonkey.com/s.aspx?sm=dyvJ9I_2fJVryteq_2fKbAZCJQ_3d_3d
The Women Scientist Advisors Committee website is http://www1.od.nih.gov/oir/sourcebook/comm-adv/wsa.htm
Initiatives to Promote Scientific Success in the NIH Intramural Program
-
- NCCAM Grantsmanship Workshop 2008 (Day 1)
-
- - NCCAM (2010/11/18)
- - Category : Conferences
- The National Center for Complementary and Alternative Medicine (NCCAM), a component of the National Institutes of Health (NIH), will conduct a 3-day grantsmanship workshop. This workshop will provide researchers, fellows, and graduate students with an in-depth understanding of the NIH grants and review processes, clarify Federal regulations and policies, and highlight areas of special interest and concern.
Emphasis will be placed on complementary and alternative medicine (CAM) research. The workshop will include time to interact and discuss research ideas with NCCAM staff. For more information, visit
http://nccam.nih.gov/news/2007/110707.htm
NCCAM Grantsmanship Workshop 2008 (Day 1)
-
- American Health Information Community - June 2008
-
- - American Health Information Community. Meeting (2010/11/18)
- - Category : American Health Information Community
- The American Health Information Community (the Community), is a committee established under the Federal Advisory Committee Act (Pub. L. No. 92-463, 5 U.S.C., App.), by the Secretary of the Department of Health and Human Services. The Community will advise the Secretary and recommend specific actions to achieve a common interoperability framework for health information technology (IT) and serve as a forum for participation from a broad range of stakeholders to provide input on achieving interoperability of health IT. The Community is made up of 17 voting members, including the Chair, and members have been appointed by the Secretary.
The Web address for the Communitys draft charter is:
http://www.hhs.gov/healthit/ahiccharter.pdf
A complete list of members can be found at:
http://www.hhs.gov/healthit/ahic.html
American Health Information Community - June 2008
-
- Third Annual HHS Computer Security and Privacy Awareness Day - 2008 (HHS Only)
-
- - HHS (2010/11/18)
- - Category : HHS Only
- On June 3, 2008, the Department will hold its third annual HHS Computer Security and Privacy Awareness Day. HHS Computer Security and Privacy Awareness Day is an excellent opportunity to raise employees awareness on a variety of security issues. Additionally, security workshops being offered during the day will help employees fulfill their HHS security training requirements.
Third Annual HHS Computer Security and Privacy Awareness Day - 2008 (HHS Only)
-
- "Circuit Neuromics": The New Path to Understanding the Genetic and Neural Causes of Mood Disorders
-
- - Akil, H.
National Institutes of Health (U.S.) (2010/11/18) - - Category : Wednesday Afternoon Lectures
- - Akil, H.
- This lecture will summarize our research aimed at understanding the biology of mood disorders, including efforts at identifying genetic vulnerability factors and at characterizing the consequences of these illnesses on the brain. It will describe a combination of genome-wide association and candidate genetic studies, post-mortem gene expression profiling and downstream analyses in animal models. It will offer examples of how these ？？？discovery approaches？？？ can lead to unexpected insights into the molecular neurobiology of mood and emotions.
This lecture will also discuss the limitations of the strategies used to date given the unique challenges intrinsic to complex brain diseases, particularly mood disorders. It will end by proposing an integrated approach, termed ？？？Circuit Neuromics？？？？？？a framework for meeting these challenges, and for discovering both the antecedents of dysregulated moods and the consequences of these disorders on brain function.
The research to be presented reflects collaborative work in the laboratories of H. Akil and S. J. Watson, as well as a broader team effort by members of an NIMH Conte Center and the Prizker Neuropsychiatric Research Consortium. Collaborators include Drs. J.D. Barchas, W.E. Bunney, E.G. Jones, R. M. Myers, A.F. Schatzberg, S.J. Watson and their colleagues.
Huda Akil is the Gardner Quarton Distinguished University Professor of Neuroscience and Psychiatry at the University of Michigan, and the co-Director of the Molecular and Behavioral Neuroscience Institute (MBNI). Dr. Akil has made seminal contributions to the understanding of the neurobiology of emotions, including pain, anxiety, depression and substance abuse. Early on, she focused on the role of the endorphins and their receptors in pain and stress responsiveness. She and her colleagues provided the first physiological evidence for a role of endorphins in the brain; and showed that endorphins are activated by stress and cause pain inhibition, a phenomenon they termed Stress-Induced Analgesia. She defined how the postranslational processing of opioid precursors is modulated by stress, and demonstrated the coordinate actions of the neuropeptide products on behavior. Her research group, in collaboration with Dr. Stanley Watson, characterized the anatomy of the opioid peptides and their receptors, cloned two types of opioid receptors and conducted structure-function analyses defining the molecular basis of high affinity and selectivity towards the endogenous ligands.
Dr. Akil has investigated the molecular and neural mechanisms underlying stress reactivity and their relation to anxiety and depression. She demonstrated that social defeat in rodents activates unique neural pathways that resemble those altered in human depression. She and her colleagues have focused on the role of the steroid stress hormone receptors in emotionality, demonstrating the involvement of the mineralocorticoid receptor in human depression. She and her collaborators have created transgenic mouse models that overexpresses either the mineralocorticoid receptor or the glucocorticoid receptor selectively in forebrain and studied the impact on anxiety and stress responses. They have shown that the glucocorticoid receptor over-expressor exhibits increased emotional lability and enhanced responsiveness to antidepressants, two features of bipolar (manic-depressive) illness.
Dr. Akil is one of the key investigators in a major research consortium using genomic tools to uncover the pattern of gene expression associated with major depression and bipolar illness in human postmortem brains. This team is currently conducting a genome-wide search for the allelic genetic variants involved in bipolar illness.
Dr. Akil？？？s scientific contributions have been recognized with numerous honors and awards. These include the Pacesetter Award from the National Institute on Drug Abuse (NIDA) in 1993, and with Dr. Stanley Watson, the Pasarow Award for Neuroscience Research in 1994. In 1998, she received the Sachar Award from Columbia University and the Bristol Myers Squibb Unrestricted Research Funds Award. Dr. Akil is the past President of the American College of Neuropsychopharmacology (1998) and the past President of the Society for Neuroscience (2004). She was elected as a Fellow of the American Association for the Advancement of Science in 2000 and to the American Academy of Arts and Sciences in 2004. In 1994, she was elected to the membership of the Institute of Medicine (IOM) of the National Academy of Science and currently serves on its Council.
More information available at
http://www.mbni.med.umich.edu/mbni/faculty/akil/akil.html
The NIH Directors Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.
"Circuit Neuromics": The New Path to Understanding the Genetic and Neural Causes of Mood Disorders
-
- NCCAM Grantsmanship Workshop 2008 (Day 2)
-
- - NCCAM (2010/11/18)
- - Category : Conferences
- The National Center for Complementary and Alternative Medicine (NCCAM), a component of the National Institutes of Health (NIH), will conduct a 3-day grantsmanship workshop. This workshop will provide researchers, fellows, and graduate students with an in-depth understanding of the NIH grants and review processes, clarify Federal regulations and policies, and highlight areas of special interest and concern.
Emphasis will be placed on complementary and alternative medicine (CAM) research. The workshop will include time to interact and discuss research ideas with NCCAM staff. For more information, visit
http://nccam.nih.gov/news/2007/110707.htm
NCCAM Grantsmanship Workshop 2008 (Day 2)
-
- Dissecting T Cell Recognition and New Directions in Human Immunology
-
- - Davis, Mark M.
National Institutes of Health (U.S.). Immunology Interest Group. (2010/11/18) - - Category : Immunology
- - Davis, Mark M.
- As a post-doctoral fellow at NIH, Dr. Mark Davis cloned the mouse TCR b chain gene, solving what had been one of the paradigmatic problems of immunology, the molecular nature of T cell receptors. He and his group have made many subsequent discoveries about genetics and structure of the T cell receptor and how it functions using molecular approaches combined with high resolution microscopy at a single molecule level. He also discovered a number of other important genes expressed by lymphocytes, including BLIMP-1, the first master regulatory gene in these cells and, with Granulysin, an important natural defence against tuberculosis. Dr. Davis has pioneered the development of diagnostic assays for immune function, first with the development of peptide-MHC tetramers which allow the precise quantitation and characterization of T cells from clinical samples and more recently, with Dr. Patrick Brown and Dr. Yueh-hsiu Chien, the invention of a high throughput cellular array system, which can obtain information about many different types of blood cells simultaneously.
Dr. Davis received his BA in molecular biology from Johns Hopkins University with Departmental Honors and his PhD in molecular biology from the California Institute of Technology. He spent three years as a postdoctoral and staff fellow with Dr. William Paul in the Laboratory of Immunology at the National Institutes of Health before going to Stanford in 1983. Dr. Davis has received numerous honors and awards, including the Behring-Heidelberger Prize from the American Association of Immunologists and the Alfred P. Sloan Prize from the General Motors Cancer Research Foundation, and is a member of the National Academy of Sciences, The American Academy of Arts and Sciences, and The Institute of Medicine.
For more information, visit
The Immunology Interest Group
Dissecting T Cell Recognition and New Directions in Human Immunology
-
- NIH Preview of the RCDC Public Webinar (NIH Only)
-
- - Krensky, Alan.
National Institutes of Health (U.S.). Office of Portfolio Analysis and Strategic Initiatives. (2010/11/18) - - Category : NIH Only
- - Krensky, Alan.
- An Introduction to the NIH Research, Condition, and Disease Categorization System. A brief presentation by the NIH Office of Portfolio Analysis and Strategic Initiatives (OPASI) followed by a Q&A session.
NIH Preview of the RCDC Public Webinar (NIH Only)
-
- Can Physical Activity and Exercise Prevent Drug Abuse? Promoting a Full Range of Science to Inform Prevention (Day 1)
-
- - National Institute on Drug Abuse. (2010/11/18)
- - Category : Conferences
- The objectives of the meeting are (1) to share the state of the science ？？？ in epidemiology, basic science and neuroscience, and intervention research ？？？ focused on physical activity as a strategy to prevent substance abuse; (2) to facilitate development and testing of new trans-theoretical paradigms for prevention; and (3) to promote future research in these areas through unsolicited grant applications and responses to targeted solicitations. We are conceptualizing physical activity and exercise quite broadly, including activities such as healthy leisure, active play, outdoor adventure, team sports, martial arts, and restorative recreation.
http://www.sei2003.com/NIDA/1014032/index.htm
Can Physical Activity and Exercise Prevent Drug Abuse? Promoting a Full Range of Science to Inform Prevention (Day 1)
-
- Can Physical Activity and Exercise Prevent Drug Abuse? Promoting a Full Range of Science to Inform Prevention (Day 2)
-
- - National Institute on Drug Abuse. (2010/11/18)
- - Category : Conferences
- The objectives of the meeting are (1) to share the state of the science ？？？ in epidemiology, basic science and neuroscience, and intervention research ？？？ focused on physical activity as a strategy to prevent substance abuse; (2) to facilitate development and testing of new trans-theoretical paradigms for prevention; and (3) to promote future research in these areas through unsolicited grant applications and responses to targeted solicitations. We are conceptualizing physical activity and exercise quite broadly, including activities such as healthy leisure, active play, outdoor adventure, team sports, martial arts, and restorative recreation.
http://www.sei2003.com/NIDA/1014032/index.htm
Can Physical Activity and Exercise Prevent Drug Abuse? Promoting a Full Range of Science to Inform Prevention (Day 2)
-
- Written Communications Skills (NIH Only)
-
- - Marguerite Meitzler, professional writer and editor (2010/11/18)
- - Category : NIH Only
- We all know the importance of good writing to a scientific career. This new three-hour workshop is for any NIH trainee who wants to improve his/her writing at the most basic level. The examples-based workshop will feature:
？？？a hands-on review of grammar, punctuation, and word usage (including, for example, subject-verb agreement, active vs. passive voice, split infinitives, agreement of pronoun and antecedent, commas, semicolons, colons, and more exotic punctuation);
？？？tips on writing and editing the perfect e-mail correspondence; and
？？？advice on organizing, writing, and editing a coherent cover letter (e.g., to accompany a resume or manuscript submission).
Individuals planning to attend may wish to purchase the recommended course text, CliffsQuickReview Writing: Grammar, Usage, and Style, in advance from the FAES Bookstore.
Written Communications Skills (NIH Only)
-
- Advisory Committee to the Director of the NIH - June 2008
-
- - Advisory Committee to the Director, National Institutes of Health. Meeting (2010/11/18)
- - Category : Advisory Committee to the Director of the NIH
- A meeting of the Advisory Committee to the Director (ACD) of the National Institutes of Health (NIH)
The agenda for the meeting will be posted at a later date on the ACD Web site at
http://www.nih.gov/about/director/acd/index.htm
Advisory Committee to the Director of the NIH - June 2008
-
- Participatory Medicine: How user-generated media are changing Americans？？？ attitudes and actions, both online and offline
-
- - Fox, Susannah.
National Institutes of Health (U.S.) (2010/11/18) - - Category : Special
- - Fox, Susannah.
- The ？？？participatory Web,？？？ also known as the realm of user-generated media and as Web 2.0, is changing the way people gather and share information online. The future of health communication and health care delivery may depend as much on these new technology developments as it does on traditional communication avenues and office visits. Today？？？s Internet users, especially those under age 35, turn to a diverse range of information sources online, many of which are created and maintained by their peers, not by credentialed experts.
Mary Madden and Susannah Fox, researchers at the Pew Internet Project, will discuss the rise of participatory medicine within the context of emerging online trends. They will review the Project？？？s methods, which rely primarily on national telephone surveys. They will then present an analysis of the many ways various demographic groups？？？such as offline seniors, omni-social teens, mobile-centric young men, and highly wired e-patients？？？use the Internet. Tracing the growth of blogs, social networking sites, wikis, and other online resources, they will then connect these findings to broader observations about privacy and health care.
Participatory Medicine: How user-generated media are changing Americans？？？ attitudes and actions, both online and offline
-
- Impact of Genomic Changes on the Treatment of Lung Cancer (NIH-Only)
-
- - Johnson, Bruce E.
National Institutes of Health (U.S.) (2010/11/18) - - Category : NCI CCR Grand Rounds (NIH Only)
- - Johnson, Bruce E.
- Bruce E. Johnson, M.D. is Director of the Carole M. and Philip L. Lowe Thoracic Oncology Program at the Dana-Farber Cancer Institute (DFCI), Director of the Dana-Farber/Brigham and Women？？？s Thoracic Oncology Program, and Leader of the Dana-Farber/Harvard Cancer Center Lung Cancer Program that includes the seven Harvard Medical School affiliated institutions.
Dr. Johnson is the Principal Investigator of the Dana-Farber/Harvard Cancer Center Specialized Program of Research Excellence (SPORE) in Lung Cancer, and holds the position of Professor of Medicine at the Brigham and Women？？？s Hospital and Harvard Medical School. Dr. Johnson earned his undergraduate degree at Harvard College and received his MD from the University of Minnesota in 1979.
He completed his postgraduate training at the University of Chicago and the National Cancer Institute (NCI). After serving at NCI, where he was head of the Lung Cancer Biology Section, he joined The Dana-Farber Cancer Institute in 1999.
His laboratory-based research is devoted to testing novel therapeutic agents for their efficacy against lung cancer and other thoracic malignancies. His group was among those that discovered that patients with partial and complete responses to the epidermal growth factor receptor inhibitors gefitinib and erlotinib have mutations in the epidermal growth factor receptor. These discoveries have been licensed to Genzyme who provides testing to identify patients with lung cancers to help select the initial treatment for patients with advanced disease. Dr. Johnson leads a research team that is applying these findings to the clinical treatment of patients with lung cancer.
Dr. Johnson is active at the national and international level. He is currently chair of the Biology subcommittee to the External Scientific Committee for the National Cancer Institute, National Human Genome Research Institute Pilot Project Characterizing Cancer Genomes. Dr. Johnson was the Chair for the Review Committee on Early Detection Research Network: Biomarkers Development Laboratory, National Cancer Institute. He served as Chair of the American Society of Clinical Oncology (ASCO) Communications Committee in 2005 and became Chair of the Education Committee in July 2007. He recently was elected to serve as a member of the ASCO Board of Directors. He serves as Senior Editor for Clinical Cancer Research and is on the Editorial Board for ？？？International Journal of Oncology？？？ and ？？？Journal of Clinical Oncology？？？. He recently received the Tisch Family Outstanding Achievement Award in Translational and Clinical Research in Solid Tumors from the Dana-Farber Cancer Institute. Dr. Johnson is a recognized expert in lung cancer, particularly small cell lung cancer. He was the Chair of the committee that drafted the National Comprehensive Cancer Network Guidelines on the treatment of small cell lung cancer.
He is currently one of four project leaders of the World Health Organization？？？s Pathology Panel, who are redefining adenocarcinoma of the lung by integrating the different genetic markers into the different types of lung cancer including bronchioloalveolar adenocarcinoma.
Dr. Johnson has authored over 145 original reports in peer-reviewed journals and more than 95 reviews, chapters and editorials.
Impact of Genomic Changes on the Treatment of Lung Cancer (NIH-Only)